Dr. Mutasem Rawas-Qalaji is a pharmaceutical researcher at Nova Southeastern University in Florida who is working on allergy tablets that will be able to serve as a stand-in for epinephrine auto injectors, or EpiPens.
Since they were first introduced in the 80s, EpiPens have been essential for treating potentially life-threatening allergic reactions. However, many patients don't like injections and are especially adverse to the idea of having to self-inject. The all-new allergy tablets work like ordinary orally disintegrating tablets, meaning that they can be held under the tongue to dissolve, which also makes them ideal for those who have trouble swallowing pills.
Across the medical industry, self-care devices are becoming less invasive, as well as more comfortable to use as a result.